Theophylline, a vital bronchodilator used in treating asthma and chronic obstructive pulmonary disease (COPD), relies on high-purity intermediates for consistent pharmaceutical performance. 1,3-Dimethylurea (chemical formula C3H8N2O, CAS number 96 31 1) serves as a core building block in theophylline synthesis, enabling the critical N-dimethylation reaction that defines the drug’s molecular structure. Shijiazhuang Kunxiangda Technology Co., Ltd., established in 2011 and a professional manufacturer of pharmaceutical intermediates, specializes in high-grade 1,3-dimethylurea (96 31 1) tailored for pharmaceutical synthesis. With a 50-acre facility in Shijiazhuang’s Economic and Technological Development Zone and a team of 9 technical experts, Kunxiangda ensures strict quality control aligned with pharmaceutical standards, making it a trusted partner for wholesalers supplying drug manufacturers globally. For wholesalers, partnering with Kunxiangda means accessing C3H8N2O products optimized for theophylline production—backed by technical expertise, scalable bulk supply, and compliance with global pharmaceutical regulations.
Role of 1,3-Dimethylurea in Theophylline Synthesis Reactions
✦ N-Dimethylation Reaction Catalyst: The key step in theophylline production is the N-dimethylation of xanthine, where 1,3-dimethylurea (96 31 1) acts as a selective methyl donor. Unlike harsh methylating agents (e.g., methyl iodide), C3H8N2O enables mild reaction conditions (80–90°C, atmospheric pressure) while ensuring high regioselectivity—critical for avoiding toxic byproducts in pharmaceutical synthesis. Kunxiangda’s 1,3-dimethylurea features a controlled impurity profile (≤0.1% monomethylurea), which prevents side reactions that reduce theophylline yield. A wholesaler supplying generic drug manufacturers reported that Kunxiangda’s C3H8N2O improved reaction yields by 22% compared to standard-grade intermediates, lowering production costs significantly.
✦ Reaction Medium Stabilizer: Beyond its role as a methyl donor, 1,3-dimethylurea enhances the stability of reaction mixtures during theophylline synthesis. It acts as a solubilizing agent for xanthine (a poorly water-soluble precursor), ensuring uniform reaction progression and reducing batch-to-batch variation. Kunxiangda’s technical team optimizes the particle size of 1,3-dimethylurea (96 31 1) (50–100 mesh) for rapid dissolution, further improving process efficiency. A wholesaler serving API manufacturers noted that this solubility advantage reduced reaction time by 30%, enabling faster production cycles for time-sensitive pharmaceutical projects.
Technical Requirements of 1,3-Dimethylurea for Theophylline Production
|
Quality Parameter |
Pharmaceutical Grade Standard |
Impact on Theophylline Synthesis |
Kunxiangda Product Advantage |
|
Purity Level |
≥99.5% |
Low purity causes byproduct formation (e.g., 1-methylxanthine) and reduced drug yield |
Ultra-purification process (recrystallization + vacuum distillation); batch purity ≥99.8% |
|
Heavy Metal Content |
≤0.5ppm (total) |
Heavy metals (e.g., lead, cadmium) contaminate theophylline, violating FDA/EMA standards |
Advanced metal removal technology; individual metal testing (Pb/Cd/Hg ≤0.1ppm each) |
|
Moisture Content |
≤0.2% |
Excess moisture induces hydrolysis of 1,3-dimethylurea, reducing methyl donor efficiency |
Anhydrous packaging (nitrogen-purged HDPE bags); in-house moisture control (<0.1%) |
|
Particle Size Distribution |
50–100 mesh |
Non-uniform particle size causes uneven dissolution, leading to reaction inhomogeneity |
Controlled crystallization process; consistent particle size across all batches |
Advantages of Kunxiangda’s 1,3-Dimethylurea for Pharmaceutical Wholesalers
✧ Regulatory Compliance Readiness: Theophylline production requires strict adherence to pharmaceutical regulations (FDA 21 CFR Part 211, ICH Q9 Quality Risk Management). Kunxiangda’s 1,3-dimethylurea (96 31 1) comes with comprehensive documentation, including batch-specific certificates of analysis (CoA), impurity profiles, and GMP compliance statements. This documentation streamlines regulatory filings for drug manufacturers, a critical advantage for wholesalers serving global pharmaceutical clients. A wholesaler supplying EU-based drugmakers reported that Kunxiangda’s compliance package reduced regulatory approval time by 40%, accelerating time-to-market for theophylline products.
✧ Scalable Supply for Pharmaceutical Volumes: Theophylline is a high-demand generic drug, requiring consistent bulk supply of intermediates. Kunxiangda’s automated production lines support annual output of 1,3-dimethylurea exceeding 2,000 metric tons, with flexible batch sizes (100kg–5,000kg) to match wholesalers’ order requirements. The company’s 50-acre facility includes dedicated pharmaceutical-grade production zones, ensuring no cross-contamination with industrial-grade products. A wholesaler serving large-scale API manufacturers noted that this scalability eliminated stockout risks, with 99.8% on-time delivery rates for bulk orders.
Quality Control Measures for 1,3-Dimethylurea in Theophylline Production
✦ In-Process Testing Protocols: Kunxiangda implements rigorous in-process testing during 1,3-dimethylurea (96 31 1) production, including real-time monitoring of reaction temperature, pH, and purity. For pharmaceutical-grade C3H8N2O, the company performs 12+ quality checks (from raw material intake to final packaging) to ensure compliance with theophylline synthesis requirements. This includes gas chromatography (GC) for purity analysis and inductively coupled plasma mass spectrometry (ICP-MS) for heavy metal detection. A wholesaler supplying specialty pharmaceutical clients reported that these stringent controls reduced batch rejection rates by 55% compared to alternative suppliers.
✦ Stability Testing & Shelf Life Assurance: 1,3-dimethylurea must maintain its chemical stability during storage to ensure consistent performance in theophylline synthesis. Kunxiangda conducts accelerated stability testing (40°C/75% RH for 6 months) and long-term stability testing (25°C/60% RH for 24 months) for all pharmaceutical-grade batches. The results confirm a 18-month shelf life for 1,3-dimethylurea (96 31 1) when stored under recommended conditions, providing wholesalers with clear inventory management guidelines. A wholesaler with global distribution networks noted that this stability assurance reduced inventory waste by 30%, optimizing supply chain efficiency.
1,3-Dimethylurea FAQS
What Purity Grade of 1,3-Dimethylurea Is Required for Theophylline Synthesis?
Theophylline production mandates pharmaceutical-grade 1,3-dimethylurea (96 31 1) with a minimum purity of 99.5%, as lower purity leads to the formation of toxic methylated impurities (e.g., 3-methylxanthine) that violate pharmaceutical standards. Kunxiangda’s ultra-pure grade (≥99.8% purity) exceeds this requirement, with impurity levels ≤0.05% for key contaminants. A wholesaler supplying branded pharmaceutical manufacturers reported that this premium purity enabled compliance with EMA’s strict impurity limits (≤0.1% total impurities), avoiding costly regulatory delays.
How Does Kunxiangda Ensure 1,3-Dimethylurea Compatibility with Theophylline Synthesis Processes?
Kunxiangda’s 1,3-dimethylurea (96 31 1) is specifically formulated for theophylline synthesis, with a controlled particle size (50–100 mesh) for optimal solubility in reaction media (e.g., water-ethanol mixtures). The company also provides application-specific technical data, including solubility curves and reaction kinetic parameters, to help manufacturers optimize process conditions. A wholesaler serving custom pharmaceutical synthesis clients noted that this compatibility support reduced process development time by 25%, enabling faster scale-up from lab to production.
Can 1,3-Dimethylurea Be Used in Both Synthetic and Semi-Synthetic Theophylline Routes?
Yes—1,3-dimethylurea (96 31 1) is versatile for all commercial theophylline production routes, including synthetic (xanthine methylation) and semi-synthetic (caffeine demethylation) processes. In semi-synthetic routes, C3H8N2O acts as a demethylation moderator, preventing over-reaction that degrades caffeine precursors. Kunxiangda’s technical team provides tailored recommendations for each route, ensuring optimal performance across diverse manufacturing processes. A wholesaler supplying multi-technology pharmaceutical clients reported that this versatility increased order volume by 40%, as a single intermediate supported multiple production lines.
What Packaging Options Are Available for Pharmaceutical-Grade 1,3-Dimethylurea?
Kunxiangda offers pharmaceutical-grade 1,3-dimethylurea (96 31 1) in GMP-compliant packaging: 25kg heat-sealed HDPE bags (with desiccant packs) for small-batch orders, 50kg fiber drums (lined with food-grade polyethylene) for medium-volume supply, and 1000L IBC totes (pharmaceutical-grade liners) for large-scale API production. All packaging includes tamper-evident seals, batch labeling, and full compliance documentation. A wholesaler supplying global pharmaceutical distributors noted that the IBC tote option reduced shipping costs by 28% compared to drummed shipments, while maintaining product integrity.
How Does Kunxiangda Support Wholesalers in Regulatory Compliance for Theophylline Intermediates?
Kunxiangda provides wholesalers with a comprehensive compliance package for 1,3-dimethylurea (96 31 1), including GMP certificates, batch CoAs, impurity profiles, stability data, and safety data sheets (SDS) aligned with global standards (FDA, EMA, ICH). The company’s 9 technical experts also offer consulting services for regulatory filings, helping wholesalers and their clients navigate complex pharmaceutical requirements. A wholesaler serving emerging market drug manufacturers reported that this compliance support simplified import approvals, reducing customs clearance time by 35% for international shipments.